Elixinol Wellness Limited (ELLXF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Elixinol Wellness Limited $0.01, price $0.00, upside +120.5%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Elixinol Wellness Limited, a holding company, produces and sells human nutrition, human wellness, pet wellness, and superfood ingredients in Australia, the Americas, and internationally. The company offers its products under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands.
Show more
Elixinol Wellness Limited, a holding company, produces and sells human nutrition, human wellness, pet wellness, and superfood ingredients in Australia, the Americas, and internationally. The company offers its products under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributes its products through grocery, wholesale, and e-commerce channels for white label customers, as well as food, beverage, and beauty manufacturers. In addition, the company engages in the manufacture and distribution of hemp-derived cannabidiol (CBD) products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is based in Newtown, Australia.
Stock analysis
Elixinol Wellness Limited (ELLXF) currently trades at $0.0034, while our model-based Fair Value estimate is $0.0075, implying the stock looks roughly 54.6% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Elixinol Wellness Limited reported revenue of A$15.5M in FY2025 versus A$9.3M in FY2021, a compound +13.5%/yr. Reported net income was −A$5.5M in FY2025.
Key figures
Market cap $1.7M · P/S ratio 0.11 · EPS (TTM) $−0.0200 · Net margin −35.5% · Return on equity −62.9% · Return on assets (EBIT) −50.0% · Operating margin −23.3% · Revenue (TTM) A$15.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 80% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 121%, ELLXF screens cheaper than that median.
Fair Value models
Bear $0.0075Fair Value $0.0075Bull $0.0075
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.12/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+167.0%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−147.3% (2020) → −32.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Elixinol Wellness Limited (ELLXF) overvalued or undervalued?
As of Jul 29, 2026, our model estimates a fair value of $0.0075 versus a price of $0.0034, about +121% upside (undervalued).
What is the fair value of ELLXF?
Our model-based fair value for Elixinol Wellness Limited is $0.0075 (as of Jul 29, 2026), built from audited fundamentals. The current price: $0.0034.
What is the quality score of ELLXF?
Elixinol Wellness Limited has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elixinol Wellness Limited (ELLXF)?
Our model-based price target is the fair value of $0.0075 (as of Jul 29, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Elixinol Wellness Limited stock forecast for 2026?
Our models put fair value at $0.0075, about +121% upside versus a price of $0.0034 (undervalued). The calculation is refreshed regularly with new filings.
What is the revenue of Elixinol Wellness Limited (ELLXF)?
Elixinol Wellness Limited reported trailing-twelve-month revenue of about A$15.5M (latest available figure, as of Jul 29, 2026).
What is the intrinsic value of Elixinol Wellness Limited (ELLXF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elixinol Wellness Limited it is $0.0075 per share (as of Jul 29, 2026), against a price of $0.0034. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Elixinol Wellness Limited stock overvalued or undervalued in 2026?
As of Jul 29, 2026, ELLXF trades below its calculated fair value: price $0.0034, fair value $0.0075, a gap of about +121% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELLXF?
No. The price is what the market pays today ($0.0034); the fair value is what the company's own numbers justify ($0.0075). For Elixinol Wellness Limited the two are $0.0041 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elixinol Wellness Limited worth?
The market values Elixinol Wellness Limited at about $1.7M (market capitalisation, as of Jul 29, 2026). Per share that is $0.0034; our models calculate a fair value of $0.0075 per share.
How far is ELLXF from its 52-week high?
Elixinol Wellness Limited trades at $0.0034, about 80% below its 52-week high of $0.0168 and 42% above the low of $0.0024 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0075 is for.
Which stocks are comparable to Elixinol Wellness Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elixinol Wellness Limited stock attractive at the current price?
The data as of Jul 29, 2026: price $0.0034, calculated fair value $0.0075 (+121%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ELLXF calculated?
We run Elixinol Wellness Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0075, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Elixinol Wellness Limited currently trades 55 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elixinol Wellness Limited (ELLXF)?
The closing price on Oct 2, 2026 was $0.0034. Our model-based fair value is $0.0075, about +121% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elixinol Wellness Limited right now?
The large discount to fair value meets weak quality (33/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.0075). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Elixinol Wellness Limited
How large is the market capitalisation of Elixinol Wellness Limited (ELLXF)?
The market capitalisation of Elixinol Wellness Limited is $1.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Elixinol Wellness Limited (ELLXF)?
The price-to-sales ratio of Elixinol Wellness Limited is 0.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Elixinol Wellness Limited (ELLXF)?
Earnings per share at Elixinol Wellness Limited are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Elixinol Wellness Limited (ELLXF)?
The net margin of Elixinol Wellness Limited is −35.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Elixinol Wellness Limited (ELLXF)?
The return on equity (ROE) of Elixinol Wellness Limited is −62.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Elixinol Wellness Limited (ELLXF)?
On an EBIT basis the return on assets of Elixinol Wellness Limited is −50.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Elixinol Wellness Limited (ELLXF)?
The operating margin of Elixinol Wellness Limited is −23.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Elixinol Wellness Limited (ELLXF)?
Revenue at Elixinol Wellness Limited is growing −4.3% versus a year earlier (3y avg +30.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Elixinol Wellness Limited (ELLXF) generate?
The free cash flow of Elixinol Wellness Limited is −A$3.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Elixinol Wellness Limited (ELLXF) carry?
The net debt of Elixinol Wellness Limited is A$2.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Thin data
Jul 29, 2026